

Quarterly trends and results

Earnings (cumulative) (JPYmn)	FY12/22				FY12/23				FY12/23	
	Q1	Q1-Q2	Q1-Q3	Q1-Q4	Q1	Q1-Q2	Q1-Q3	Q1-Q4	% of forecast	FY forecast
Sales	2,316	4,874	7,356	10,008	1,545	3,179	4,421		78.9%	5,603
YoY	63.1%	54.9%	32.5%	21.2%	-33.3%	-34.8%	-39.9%			-44.0%
Gross profit	1,898	4,010	5,467	7,600	1,243	2,473	3,476			
YoY	87.9%	76.3%	35.1%	31.0%	-34.5%	-38.3%	-36.4%			
Gross profit margin	82.0%	82.3%	74.3%	75.9%	80.5%	77.8%	78.6%			
SG&A expenses	1,389	2,638	3,878	5,636	1,192	2,523	3,759			
YoY	13.8%	6.8%	7.1%	17.8%	-14.2%	-4.4%	-3.1%			
SG&A ratio	60.0%	54.1%	52.7%	56.3%	77.2%	79.4%	85.0%			
Operating profit	509	1,372	1,589	1,964	51	-50	-283		-	-680
YoY	-	-	274.5%	93.3%	-89.9%	-	-		-	-
Operating profit margin	22.0%	28.2%	21.6%	19.6%	3.3%	-	-		-	-
Recurring profit	479	1,447	1,843	2,000	48	67	-156		-	-549
YoY	-	-	344.8%	99.8%	-89.9%	-95.4%	-		-	-
Recurring profit margin	20.7%	29.7%	25.1%	20.0%	3.1%	2.1%	-		-	-
Net income	163	1,108	1,556	1,179	4	-80	-789		-	-1,291
YoY	-	-	378.9%	-42.0%	-97.3%	-	-		-	-
Net margin	7.0%	22.7%	21.2%	11.8%	0.3%	-	-		-	-
Earnings (quarterly) (JPYmn)	FY12/22				FY12/23				FY12/23	
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4		
Sales	2,316	2,558	2,482	2,653	1,545	1,634	1,242			
YoY	63.1%	48.2%	3.1%	-1.9%	-33.3%	-36.1%	-49.9%			
Gross profit	1,898	2,112	1,456	2,133	1,243	1,230	1,003			
YoY	87.9%	67.0%	-17.8%	21.6%	-34.5%	-41.8%	-31.1%			
Gross profit margin	82.0%	82.6%	58.7%	80.4%	80.5%	75.3%	80.7%			
SG&A expenses	1,389	1,249	1,240	1,759	1,192	1,331	1,237			
YoY	13.8%	0.0%	7.6%	51.3%	-14.2%	6.5%	-0.3%			
SG&A ratio	60.0%	48.8%	50.0%	66.3%	77.2%	81.5%	99.5%			
Operating profit	509	863	216	375	51	-101	-233			
YoY	-	-	-65.0%	-36.7%	-89.9%	-	-			
Operating profit margin	22.0%	33.8%	8.7%	14.1%	3.3%	-	-			
Recurring profit	479	969	396	156	48	19	-223			
YoY	-	-	-35.9%	-73.3%	-89.9%	-	-			
Recurring profit margin	20.7%	37.9%	16.0%	5.9%	3.1%	1.1%	-			
Net income	163	945	448	-377	4	-84	-709			
YoY	-	-	-15.6%	-	-97.3%	-	-			
Net margin	7.0%	36.9%	18.0%	-	0.3%	-	-			

Source: Shared Research based on company data

Note: Figures may differ from company materials due to differences in rounding methods.

Note: "-" denotes YoY change of over 1,000%.

Note: Starting from FY12/22, the company switched to preparing consolidated financial statements in connection with the commencement of full-fledged operations at SymBio Pharma USA. As data for FY12/22 are on a consolidated basis, YoY comparisons are for reference only.

Breakdown of SG&A expenses

Earnings (cumulative) (JPYmn)	FY12/22				FY12/23			
	Q1	Q1-Q2	Q1-Q3	Q1-Q4	Q1	Q1-Q2	Q1-Q3	Q1-Q4
SG&A expenses	1,389	2,638	3,878	5,636	1,192	2,523	3,759	
YoY	13.8%	6.8%	7.1%	17.8%	-14.2%	-4.4%	-3.1%	
R&D expenses	496	1,009	1,564	2,555	550	1,204	1,824	
YoY	4.8%	10.6%	21.6%	47.2%	10.8%	19.3%	16.6%	
SG&A expenses excl. R&D	893	1,629	2,314	3,081	642	1,319	1,936	
YoY	19.5%	4.6%	-0.9%	1.1%	-28.1%	-19.0%	-16.4%	
Earnings (quarterly) (JPYmn)	FY12/22				FY12/23			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
SG&A expenses	1,389	1,249	1,240	1,759	1,192	1,331	1,237	
YoY	13.8%	0.0%	7.6%	51.3%	-14.2%	6.5%	-0.3%	
R&D expenses	496	513	554	991	550	654	620	
YoY	4.8%	16.9%	48.2%	120.3%	10.8%	27.4%	11.8%	
SG&A expenses excl. R&D	893	736	686	767	642	677	617	
YoY	19.5%	-9.2%	-11.9%	7.7%	-28.1%	-8.0%	-10.0%	

Source: Shared Research based on company data

Note: Figures may differ from company materials due to differences in rounding methods.

Cumulative Q3 FY12/23 results

- Sales: JPY4.4bn (-39.9% YoY)
- Operating loss: JPY283mn (versus an operating profit of JPY1.6bn in cumulative Q3 FY12/22)
- Recurring loss: JPY156mn (versus a recurring profit of JPY1.8bn in cumulative Q3 FY12/22)
- Net loss attributable to owners of the parent: JPY789mn (versus a net income of JPY1.6bn in cumulative Q3 FY12/22)

In February 2022, SymBio obtained approval for a partial change to the marketing authorization for the ready-to-dilute (RTD) intravenous formulation of TREAKISYM® 100mg/4ml, which was launched in January 2021, to add rapid infusion (RI) administration. Compared to the freeze-dried (FD) formulation, the RTD formulation reduces the time required for the complicated dissolution process. RI administration further benefits both patients and healthcare providers by reducing the infusion time from the 60 minutes required by the RTD formulation. In addition, the RI administration uses less saline solution and accordingly less salt (sodium chloride).

The switch from the FD to RTD formulation is almost complete. With over 90% of medical institutions administering the RI formulation to patients as of end-September 2023, progress was made in the switch to the RI formulation. On the quality assurance front, SymBio also has taken steps to ensure the stable supply of the RTD formulation of TREAKISYM®.

Sales decreased by 39.9% YoY to JPY4.4bn. This decline can be attributed to several factors: firstly, the reduced amount of drugs used per patient due to the impact of COVID-19 and seasonal flu; secondly, the launch of generic drugs in June 2022, which affected SymBio's product sales. Additionally, there was a temporary sales spike in the same period last year resulting from the switch from the FD formulation to the RTD formulation, which impacted this year's sales.

Gross profit totaled JPY3.5bn (-36.4% YoY) and the gross profit margin was 78.6% (+4.3pp YoY). SG&A expenses came to JPY3.8bn (-3.1% YoY), including R&D expenses of JPY1.8bn (+16.6% YoY). As a result, the company recorded an operating loss of JPY283mn (versus an operating profit of JPY1.6bn in cumulative Q3 FY12/22).

Establishment of an in-house sales organization

The business alliance agreement between SymBio and Eisai Co., Ltd. under which Eisai acts as a sales agent expired in December 2020, and the company switched to in-house sales for domestic sales of Treakisym®.

In conducting in-house sales, SymBio established a sales organization that can cultivate needs, provide information on the company products, and plan seminars. In addition to medical representatives, the company deployed hematology experts with extensive knowledge of the field throughout Japan. Further, the company concluded basic agreements with Suzuken Co., Ltd and Toho Pharmaceutical Co., Ltd for the procurement and sale of pharmaceuticals to build a nationwide distribution network. The company has established two distribution centers, one in Eastern Japan and the other in Western Japan, under management by S.D. Collabo Co., Ltd.

Anticancer agent SyB L-0501 (FD formulation)/SyB L-1701 (RTD formulation)/SyB L-1702 (RI administration); generic name: bendamustine hydrochloride or bendamustine hydrochloride hydrate, product name: Treakisym®

In March 2021, SymBio obtained approval for the use of the FD formulation of TREAKISYM® in BR therapy to treat r/r DLBCL as an additional indication. In February 2022, the company secured approval for a partial amendment to the marketing authorization for the ready-to-dilute (RTD) formulation of TREAKISYM® (in-licensed from US-based Eagle Pharmaceuticals, Inc.), enabling the use of RI administration for all approved indications of the RTD formulation.

SymBio will continue to explore new potential applications of TREAKISYM®, including via joint research with Kyoto University.

Anticancer agent SyB L-1101 (IV)/SyB C-1101 (oral); generic name: rigosertib sodium

For rigosertib and TREAKISYM®, the company is searching for new indications as well as new applications for the drugs used in combination with each other or with other existing drugs, through joint research and the offering of academia-industry collaborative courses with the University of Tokyo.

Antiviral drug SyB V-1901 (generic name: brincidofovir)

In development of the intravenous and oral formulations of the antiviral drug brincidofovir (SyB V-1901; BCV IV and BCV Oral), the company is conducting joint research with top research institutions specialized in each field in Japan and overseas in light of the broad spectrum of the drug's effectiveness against dsDNA virus infections. It will consider conducting additional global clinical trials based on the scientific findings of the research.

Earlier clinical trials in the US and Europe conducted by US-based Chimerix Inc. have demonstrated that BCV Oral has broad-spectrum antiviral effects against a variety of dsDNA viruses. BCV IV is expected to be effective and safe for the prevention and treatment of many dsDNA virus infections, including adenovirus (AdV) infections after hematopoietic stem cell transplantation. In June 2021, Chimerix announced that the US FDA had granted BCV Oral approval for the treatment of smallpox.

In September 2022, Chimerix announced that it had completed procedures to transfer the rights to brincidofovir to Emergent BioSolutions Inc. (headquarters: Maryland, US). The agreement, however, has no impact on the company's exclusive rights to develop, manufacture, and sell brincidofovir globally for all indications except orthopoxvirus diseases including smallpox and monkeypox.

Based on a global advisory board review held in February 2020, the company has decided to prioritize the global development of BCV IV primarily in Japan, the US, and Europe, targeting disseminated AdV infections occurring after hematopoietic stem cell transplantation, a niche area with a high unmet medical need. In March 2021, the company filed an IND application with the US Food and Drug Administration (FDA) to conduct a Phase II clinical trial primarily in pediatric patients suffering from AdV infections (also including adults). This development program was granted fast-track designation by the FDA in April 2021, and the investigational drug was administered to the first patient in August 2021. In May 2023, BCV has demonstrated proof of concept in humans in the same study. Positive data demonstrating efficacy from the study will be presented orally at the 65th Annual Meeting of the American Society of Hematology in December 2023.

BK virus nephropathy after kidney transplantation is considered a disease with serious consequences for the recipient, the donor, the medical practitioner, and society, as it may result in serious conditions such as decreased renal function and graft loss. In order to find an early solution to this problem, Symbio submitted a clinical trial notification for a global Phase II study in patients infected with BK virus after receiving kidney transplant to the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan in May 2022 and to the Therapeutic Goods Administration (TGA) of Australia in August 2022. The investigational drug was administered to the first patient in Australia in August 2022. While the trial was initially planned for completion in 2025, delays in the accumulation of cases have led to a review of the protocol.

In November 2022, the company concluded a material transfer agreement (MTA) with US-based Penn State College of Medicine, and initiated a non-clinical study evaluating the efficacy of BCV in a mouse model of polyomavirus infection.

In addition to antiviral activity, the company expects brincidofovir to have antitumor effects. Through joint research with the National Cancer Centre Singapore and University of California San Francisco Brain Tumor Center, Symbio is investigating new indications for the drug in oncology, including rare brain tumors and EB virus-positive lymphoma. In March 2022, the company commenced joint research with Brown University of the US to investigate the antitumor effects of brincidofovir on glioblastoma (GBM) caused by cytomegalovirus (CMV) infection.

In December 2022, the results of collaborative research with the National Cancer Centre Singapore (NCCS) on the therapeutic efficacy of BCV in the treatment of rapidly progressing NK/T-cell lymphoma were presented at the 64th American Society of Hematology (ASH) Annual Meeting.

At the 17th International Conference on Malignant Lymphoma (ICML) in June 2023, research into biomarkers that predict the anti-tumor effect of BCV was presented.

Symbio has been preparing for clinical development of brincidofovir for multiple sclerosis, a rare disease related to EB virus. In August 2022, the company signed a collaboration agreement for the transfer of human materials with the National Institute of Neurological Disorders and Stroke (NINDS) of the US National Institute of Health (NIH). In March 2023, Symbio signed a cooperative research and development agreement (CRADA) with NINDS to obtain information necessary to conduct future clinical trials. In October 2023, the results of the research were presented at the 9th Joint ECTRIMS-ACTRIMS Meeting in Milan, Italy.

In April 2023, Symbio also signed a CRADA with the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, to evaluate the efficacy of BCV in EB virus-related lymphoproliferative disorders.

In December 2022, the company concluded a sponsored research agreement with US-based Tufts University, and began a joint research study evaluating the efficacy of BCV in a herpes simplex virus infection model. This study aims to explore BCV's potential to treat neurological diseases, including Alzheimer's disease.

Overseas (Symbio Pharma USA)

In August 2023, the company appointed Dr. Stephane Berthier as CEO and President of its wholly-owned subsidiary Symbio Pharma USA, Inc. In September 2023, Symbio added Nkechi Azie, MD, as Global Chief Medical Officer (CMO) to further reinforce its global development structure. Symbio Pharma USA plans to accelerate global development of the antiviral drug brincidofovir.

In-licensing of drug candidates

The company is currently focusing on unrolling global development plans for the antiviral drug brincidofovir it in-licensed in September 2019, but also constantly looking into multiple licensing deals and looking for and evaluating promising new in-licensing drug candidates.

FY12/23 company forecast (revised in August 2023)

(JPYmn)	FY12/22			FY12/23			YoY
	1H results	2H results	FY results	1H results	2H forecast	FY forecast	
Sales	4,874	5,135	10,008	3,179	2,424	5,603	-44.0%
Operating profit	1,372	591	1,964	-50	-630	-680	-
Operating profit margin	28.2%	11.5%	19.6%	-	-	-	-
Recurring profit	1,447	553	2,000	67	-616	-549	-
Recurring profit margin	29.7%	10.8%	20.0%	2.1%	-	-	-
Net income	1,108	71	1,179	-80	-1,211	-1,291	-
Net margin	22.7%	1.4%	11.8%	-	-	-	-

Source: Shared Research based on company data.

Note: Figures may differ from company materials due to differences in rounding methods.

Full-year FY12/23 company forecast (revised on November 14, 2023)

In November 2023, the company announced a revision to its full-year company forecast for FY12/23. The revised company forecast is as follows:

- Sales: JPY5.6bn (previous forecast: JPY6.5bn)
- Operating loss: JPY680mn (previous forecast: operating loss of JPY331mn)
- Recurring loss: JPY549mn (previous forecast: recurring loss of JPY219mn)
- Net loss attributable to owners of the parent: JPY1.3bn (previous forecast: net loss of JPY370mn)

Reasons for revision

- ▶ In comparison to the previous forecast, the company has downwardly revised its sales forecast by JPY874mn to JPY5.6bn. Although the impact of bendamustine generics generally met the company's expectations, the decline in drug usage per case of malignant lymphoma treatment, coupled with treatment delays, persisted due to the influence of seasonal flu and COVID-19.
- ▶ The company has revised its operating loss forecast to a loss of JPY680mn, a decrease of JPY349mn from the previous forecast. While prioritizing R&D investments for the global development of brincidofovir (BCV), the company has been reviewing expenses to reduce SG&A expenses. However, this was not sufficient to compensate for the decrease in sales. The company has also revised its recurring loss forecast to JPY549mn, a decrease of JPY330mn from the previous forecast, despite forex valuation gains on foreign currency-denominated assets.
- ▶ As a result of evaluating the recoverability of deferred tax assets in the future, the company has decided to reverse JPY642mn of deferred tax assets and record deferred income taxes at the end of FY12/23. As a result, the company has reduced its forecast for net loss attributable to owners of the parent by JPY921mn from the previous forecast to JPY1.3bn.

About Shared Research Inc.

We offer corporate clients comprehensive report coverage, a service that allows them to better inform investors and other stakeholders by presenting a continuously updated third-party view of business fundamentals, independent of investment biases. Shared Research can be found on the web at <https://sharedresearch.jp>.

Contact Details

Company name

Shared Research Inc.

Phone

+81 (0)3 5834-8787

Address

2-6-10 Kanda-Sarugakucho Chiyoda-ku Tokyo, Japan

Email

info@sharedresearch.jp

Website

<https://sharedresearch.jp>

Disclaimer

This document is provided for informational purposes only. No investment opinion or advice is provided, intended, or solicited. Shared Research Inc. offers no warranty, either expressed or implied, regarding the veracity of data or interpretations of data included in this report. We shall not be held responsible for any damage caused by the use of this report. The copyright of this report and the rights regarding the creation and exploitation of the derivative work of this and other Shared Research Reports belong to Shared Research. This report may be reproduced or modified for personal use; distribution, transfer, or other uses of this report are strictly prohibited and a violation of the copyright of this report. Our officers and employees may currently, or in the future, have a position in securities of the companies mentioned in this report, which may affect this report's objectivity.

Japanese Financial Instruments and Exchange Law (FIEL) Disclaimer: The report has been prepared by Shared Research under a contract with the company described in this report ("the company"). Opinions and views presented are ours where so stated. Such opinions and views attributed to the company are interpretations made by Shared Research. We represent that if this report is deemed to include an opinion from us that could influence investment decisions in the company, such an opinion may be in exchange for consideration or promise of consideration from the company to Shared Research.